| Heading: |
HIV Infection: Preventive Medicine |
| Question ID: |
1792800 |
| UIN: |
44568 |
| House: |
Commons |
| Date tabled: |
2025-04-07 |
| Asking Member ID: |
4799 |
| Asking Member display name: |
Charlotte Nichols
|
| Asking Member handle: |
charlotte2153
|
| Asking Member Twitter reference: |
@charlotte2153
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what steps he plans to take to support the scale up of the provision of long-acting HIV prevention medicines now entering the market. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-28 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4264 |
| Answering Member display name: |
Stephen Doughty
|
| Answering Member handle: |
SDoughtyMP
|
| Answering Member Twitter reference: |
@SDoughtyMP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The UK remains committed to sustainable development goal 3.3 in ending HIV as a public health threat by 2030. Long-acting technologies have the potential to be game-changers in the global response to HIV, but only if they reach the countries and communiti... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
208 |
| Answering body name: |
Foreign, Commonwealth and Development Office |
| Tweeted: |
true |